Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

sen is

currently in phase 3 development for patients with homozygous familial

hypercholesterolemia, and a U.S. marketing application for this

indication is anticipated in 2009. The product offers an innovative

approach to addressing a real, unmet medical need, and Genzyme believes

it could prove to be the most effective lipid-lowering agent for high

risk cardiovascular disease patients for whom conventional therapies

are not sufficient. The product may potentially provide significant

benefit over the standard of care and targets a well-defined and

severely ill patient population.

Alemtuzumab for multiple sclerosis

-- Genzyme is enrolling patients in two phase 3 trials examining the

safety and efficacy of alemtuzumab for the treatment of multiple

sclerosis. One study includes previously untreated patients and one

involves patients whose disease remains active following treatment with

an approved therapy. Alemtuzumab's effect in treating MS, observed in

clinical studies, exceeds that of any currently marketed products and

any products in development. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is investing in the development of an innovative, next-

generation product for the treatment of Gaucher disease. The company

has completed enrollment in a phase 2 trial of the small molecule

Genz-112638, a novel oral therapy that could provide an additional

treatment option for physicians and patients. Initial results for the

first group
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Investing ” was featured on NewsWatch as part of its ... and large businesses making an impact in their industry. Andrew ... business review and shared with viewers how this website and ... , The idea, “let your money work for you” is ... to succeed are two different things. So if a ...
(Date:5/28/2015)... MA (PRWEB) May 28, 2015 Workers’ compensation ... the typical state, a recent study by the Workers ... falling over a three-year period. , The WCRI study, ... in which workers missed seven days or more of work ... months, the average 2011 Michigan claim was 4 percent lower ...
(Date:5/28/2015)... Nidra Herbal Sleep Supplement features a 100% Ayurveda ... non-addictive supplement, Nidra Herbal Sleep Supplement is more than just ... users with a real sense of wellbeing the next day. ... translates as the “Science or Knowledge of Life”, was first ... a holistic system of knowledge which combines contemplation, herbal supplements ...
(Date:5/28/2015)... Ticket Down is a reputable source of ... Mexico and Argentina in early September. , Two of ... on the pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico ... friendly on Tuesday, September 8th at 9 p.m. The match ... world including some of the most loved players in the ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Healthpointe ... will now be offering Echocardiography Examinations to patients ... performed by renowned Qualified Medical Examiner and licensed ... echocardiography test is a non-invasive and cost-effective approach ... are critically ill or have undergone surgery. ...
Breaking Medicine News(10 mins):Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Ayurveda Herba Corp’s Revolutionary Herbal Sleep Supplement is Now Available from Amazon.com 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2
... May 26 Alexian Brothers Medical Center dedicated ... May 21. The 200,000 square-foot, five-story, patient ... to all private rooms, and will centralize all ... resonance imaging (MRI), diagnostic imaging, nuclear medicine, ultrasound ...
... home, nearly 1 million Californians cross the border each ... new paper by UCLA researchers and colleagues published today ... , An estimated 952,000 California adults sought medical, ... these, 488,000 were Mexican immigrants, according to the research ...
... 26 The Community Oncology Alliance (COA) announced today ... Demonstration (QCCD) project, a landmark initiative to transform ... focus on patients covered by Medicare (approximately 45% of ... of a patient-centric program that enhances quality cancer care ...
... ORLANDO (May 30, 2009)When a cancer patient and his or ... conversation usually centers on a consideration of the treatment,s medical ... however, as the already high costs of cancer care continue ... also take into account the economic impact of the treatment ...
... in Program to Help Local Producers Grow Businesses; ... May 26 Whole Foods Market (Nasdaq: ... foods supermarket, announced today that its Local Producer ... States with $2.5 million in low-interest loans.Whole Foods ...
... Behavior Support Strategies for Children with Developmental Disabilities ... education report from the U.S. Government Accountability Office ... seclusions in schools can lead to abuse and ... Positive Behavior Support (PBS) has emerged in recent ...
Cached Medicine News:Health News:Alexian Brothers Medical Center Opens New Patient Tower 2Health News:Nearly 1 million Californians seek medical care in Mexico annually 2Health News:Nearly 1 million Californians seek medical care in Mexico annually 3Health News:Call to Action: Community Oncologists Propose 'Roadmap' to Reformed Payment System for Cancer Care; Quality Cancer Care Demonstration Project Will Create System, Enhancing Quality Cancer Care While Controlling Costs 2Health News:Call to Action: Community Oncologists Propose 'Roadmap' to Reformed Payment System for Cancer Care; Quality Cancer Care Demonstration Project Will Create System, Enhancing Quality Cancer Care While Controlling Costs 3Health News:Can we afford the cancer care of the future? 2Health News:Whole Foods Market(R) Lends $2.5 Million to Local Growers, Producers and Food Artisans 2Health News:Whole Foods Market(R) Lends $2.5 Million to Local Growers, Producers and Food Artisans 3Health News:Positive Behavior Support Is the Progressive Alternative to Restraints and Seclusion in Schools 2Health News:Positive Behavior Support Is the Progressive Alternative to Restraints and Seclusion in Schools 3
(Date:5/28/2015)... , May 27, 2015 The amount ... billion in 2014 and with growth of 8% will ... categories out of pocket: directly on expenditures, co-pays as ... purchases, and on premiums.  The publisher made its finding ... in the United States . ...
(Date:5/28/2015)... -- The U.S. Department of Justice (DOJ) has entered into ... Inc. to resolve a lawsuit that began more than ... lawsuit by two former employees of Orbit.  The whistleblowers ... one of Orbit,s top executives, Jake Kilgore , ... from Medicare for electric wheelchairs.  The lawsuit was brought ...
(Date:5/28/2015)... , May 28, 2015 ... "Global mHealth Market (Device, Service, Application, Stakeholders and Geography) - ... 2014-2020", stated that the global mHealth market was ... expected to grow at a CAGR of 33.5% ... share in the global mHealth device market followed ...
Breaking Medicine Technology:Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 2mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 3mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 4
... SPRING, Md., April 19, 2011 The Food and ... the root of misuse, misprescribing, abuse, overdoses, addiction, and ... of these powerful opioids? (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm251830.htm Sign up for e-mail ...
... 19, 2011 Amira Pharmaceuticals, Inc. announced today that ... an orphan drug designation by the U.S. Food and ... Commonly referred to as IPF, this fibrotic disease affects ... "This is an important development for Amira, ...
Cached Medicine Technology:Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis 2
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
... aliquot! The aliquot from Genetix is a ... 96, 384, and 1536 well microplates. With ... facility and optional microplate stacker, the aliquot ... volume dispensing needs. The aliQuot's compact design ...
... Tecan introduces the new Nanopipetting System Genesis ... This latest technology allows you to miniaturize ... applications like hit picking and direct dilutions., ... for array pipetting applications including gene expression ...
... system for fast, accurate filling of 96 or ... controlled dispensing mechanism, ensures that no liquid can ... that come into contact with the liquid path ... unique compact design saves valuable bench space and ...
Medicine Products: